Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cullin-associated NEDD8-dissociated protein 2 (CAND2) is a regulatory protein predominantly found in mammals, with tissue enrichment in cardiac and skeletal muscle cells. It is a homolog of CAND1 and functions by binding to Cullin-1, facilitating the dynamic exchange of F-box proteins in the SCF (SKP1–CUL1–F-box protein) E3 ubiquitin ligase complexes, thereby promoting selective protein degradation within the cell. CAND2 is less globally efficient than CAND1 but is selectively important in specific tissues. Its disruption modifies the turnover of hundreds of proteins, impacting cellular and organismal health, with genetic links to heart disease and metabolic disorders. The protein’s molecular mechanism, expression patterns, and disease associations suggest roles as a risk modifier and candidate biomarker, but as of now there are no approved drugs directly targeting CAND2.
Not applicable; no existing drugs known to directly target CAND2. Hypothetically, future molecules could inhibit or enhance CAND2-mediated SCF assembly, thus affecting ubiquitin-dependent protein degradation and downstream cellular signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cullin-associated NEDD8-dissociated protein 2 (CAND2).